Hormone replacement therapy (HRT): Overview and focus on progestogens
This promotional webinar has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0346 March 2022
Managing iron deficiency anaemia
Information intended for UK healthcare professionals only. These promotional videos have been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines and Guidelines Live. Promotional information regarding Norgine Pharmaceutical Limited products will be presented.
View FERACCRU® (ferric maltol) prescribing information and adverse event reporting information here
UK-HAE-FER-2200012
Date of preparation: May 2022
Hormone replacement therapy (HRT): what is the role of the progestogen?
This promotional video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0362 March 2022
Targeting the cause of opioid-induced constipation with PAMORAs
This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141580 | Date of preparation: September 2021
Management of obesity in primary care: a Guidelines algorithm
Information intended for UK healthcare professionals only. These videos have been funded through an arm’s-length sponsorship by Novo Nordisk Limited. Guidelines approached Novo Nordisk Limited to fund the production of these videos.
Date of preparation: December 2021
Diagnosis and initial management of opioid-induced constipation
This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141579 | Date of preparation: September 2021
Opioid-induced constipation: optimal management and the role of PAMORA drugs
These promotional videos have been funded by Sandoz Ltd and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141578 | Date of preparation: September 2021
Management of common eye conditions: corneal and subtarsal foreign bodies
Sarah Thomas (Moorfields Eye Hospital NHS Foundation Trust) covers the symptoms and treatment of foreign bodies in the eye.
Management of common eye conditions: Glaucoma and the #knowyourdrops campaign
Sarah Thomas (Moorfields Eye Hospital NHS Foundation Trust) discusses treatment of glaucoma and techniques for correct eye drop administration.
Dr Glenis Scadding Q&A on rhinitis
This session was supported by an educational grant from Mylan Ltd. Dr Glenis Scadding comments on the main presentations of rhinitis, its impact on patients’ daily lives, red flags for referral, and the main recommendations of the 2017 BSACI guideline
Dr Kevin Fernando Q&A on type 2 diabetes
Dr Kevin Fernando answers questions on the impact of type 2 diabetes on patients’ daily lives, differences between NICE and SIGN guidance, and key take-home messages for primary care
Liraglutide 6 mg/ml solution for injection in pre-filled pen (Saxenda®) SMC2455
Information intended for UK healthcare professionals only. The production of this Guidelines card has been commissioned by Novo Nordisk Limited.
View Saxenda® (liraglutide 3 mg) Great Britain and Northern Ireland prescribing information and adverse event reporting information.
UK22SX00249
Date of preparation: June 2022
Sixmo®▼ (buprenorphine) 74.2mg implant SMC2372
The production of this Guidelines card has been commissioned by Accord Healthcare Limited.
View adverse event reporting and prescribing information
UK-03735 April 2022
Trixeo® Aerosphere® (formoterol fumarate, glycopyrronium, and budesonide)
This promotional prescribing summary card has been developed from content provided by AstraZeneca Limited. Information intended for UK healthcare professionals only.
View Trixeo (formoterol fumarate dihydrate/ glycopyrronium/ budesonide) prescribing information and adverse event reporting information
View Bevespi (glycopyrronium/formoterol fumarate dihydrate) prescribing information and adverse event reporting information
GB-37843
Date of preparation: July 2022
Malnutrition and FORCEVAL® Capsules
This prescribing summary card was developed from content provided by Alliance Pharma in a format developed by Guidelines Information intended for UK healthcare professionals only.
View Forceval® Capsules prescribing and adverse event reporting information.
JB-001493 June 2022
DuoResp® Spiromax® (budesonide/formoterol)
This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.
Click here for prescribing information and adverse event reporting
DUOR-GB-00117
Date of preparation: March 2022
WEBINAR REPORT: Best practice: Management of mental health in patients with acne
This report and the webinar have been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines and Guidelines in Practice.
June 2022
A national audit of pancreatic enzyme replacement therapy (PERT) prescribing in patients with pancreatic cancer: The RICOCHET study
This supplement has been commissioned and funded by Viatris and developed in partnership with Guidelines.
NON-2021-4065 February 2022
Best practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure
This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.
Management of hepatic encephalopathy in primary care
This management algorithm has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
View TARGAXAN® (rifaximin-α) prescribing and adverse event reporting information
UK-HEP-XIF-2100040 October 2021
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.
Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone
This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021
Managing obesity in primary care
This management algorithm was developed by a multidisciplinary expert panel: Tahrani et al with the support of an educational grant from Novo Nordisk Limited. Information intended for UK healthcare professionals.
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.
Women of child-bearing age with inflammatory rheumatic diseases guideline
This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.
Medication management of patients with enteral feeding tubes
This guideline was developed by a multidisciplinary expert panel: Wright D et al with the support of a grant from Rosemont Pharmaceuticals Ltd.
Anticoagulation management for elderly patients with NVAF, CKD and other comorbidities
This promotional webinar was organised and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals only.
Click HERE to view ELIQUIS (apixaban) prescribing information and adverse events reporting
Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK).
432-GB-2200204 May 2022
Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care
This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only.
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021
Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2416 March 2022
Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study
This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto▼(rivaroxaban)
PP-XAR-GB-2415 January 2022
Management of venous thromboembolism in primary care
This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100953 | February 2022